Switzerland news - the latest biotech news from Labiotech.eu

Home Switzerland Page 3

Latest Posts

Philipp Spycher Araris Biotech

News and Trends 21 Dec 2022

Watch: Araris Biotech at Bio-Europe

Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug-conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

20210715 PDCLP lab2 17 scaled 1

News and Trends 8 Dec 2022

PDCline Pharma presents first immunological results from trial with PDClung01

PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […]

December 8, 2022 - 3 minutesmins - By Liza Laws

covid covid-19

News and Trends 8 Dec 2022

MetrioPharm reveals COVID-19 study data

MetrioPharm AG, a Swiss pharmaceutical company developing drugs for inflammatory diseases, has announced topline data from its CT05 phase IIa study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients. In the trial, patients received either MP1032 plus standard of care (SoC), or placebo plus SoC. SoC partially included other antivirals (Remdesivir or Nirmatrelvir/Ritonavir), […]

December 8, 2022 - 4 minutesmins - By Jim Cornall

leukaemia leukemia

News and Trends 8 Dec 2022

Laevoroc Oncology pushes for relapsed leukemia cure

Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune […]

December 8, 2022 - 2 minutesmins - By Jim Cornall

shutterstock central nervous system

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]

December 7, 2022 - 3 minutesmins - By Liza Laws

lung cancer

News and Trends 6 Dec 2022

INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer

OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant and its European partners in biotechnology, medical devices, cancer research, academia and patient advocacy, met in Galway, Ireland, for the official kick-off […]

December 6, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT

ovarian cancer

News and Trends 28 Nov 2022

Localizing BRCA gene mutations to better treat ovarian cancer

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer. In 2016, a new class of drugs, PARP inhibitors, was found to be highly effective against BRCA mutation-related tumors. However, almost […]

November 28, 2022 - 5 minutesmins - By Jim Cornall

gene editing

News and Trends 21 Nov 2022

FMRP – the protein behind immunotherapy resistance

Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success rates, immunotherapy has time and again met with a stubborn obstacle: tumor cells often evade the “radar” of immune cells seeking to destroy them. This in turn leads to treatment resistance, which in many cases […]

November 21, 2022 - 6 minutesmins - By Jim Cornall

c elegans nagi bioscience Elena Resko

Startup Scout 15 Nov 2022

Nagi Bioscience tests drugs on worms using microfluidics

The Swiss startup Nagi Bioscience aims to speed up drug and chemical safety testing by automating research on a worm called Caenorhabditis elegans. For companies developing a drug or chemical product, there are many ways to predict the safety of their compound in humans. They can test the drugs in cell cultures, which are cheap […]

November 15, 2022 - 5 minutesmins - By Jonathan Smith

macrophage

News and Trends 10 Nov 2022

Researchers develop new nanoparticle to deliver drugs direct to macrophages

How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to […]

November 10, 2022 - 4 minutesmins - By Jim Cornall

shutterstock paralysis

More News! 9 Nov 2022

Wyss Center’s ABILITY system to improve quality of life for people with severe paralysis

The Wyss Center for Bio and Neuroengineering has shared the latest signals recorded by its fully plantable ABILITY brain computer interface (BCI) at a Society for Neuroscience meeting. ABILITY is designed to improve quality of life and independence for people with severe paralysis and demonstrates safety and efficacy in pre-clinial trials. New details of the […]

November 9, 2022 - 3 minutesmins - By Liza Laws

data

News and Trends 8 Nov 2022

BC Platforms receives $20M financing

Healthcare data management and analytics company BC Platforms (BCP) has closed a CHF 20 million ($20 million) financing round. The growth equity financing was led by new investor Jolt Capital (HQ Paris), a fully independent private equity firm that specializes in growth capital deeptech in Europe. The new financing will help accelerate the expansion of […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT